Pharma channel feed

Bay­er buys Eu­ro­pean rights to Bridge­Bio's AT­TR-CM pill

Last year
Deals

En­do inks $465M bank­rupt­cy deal set­tling crim­i­nal and civ­il opi­oid cas­es

Last year
Law

GAO di­rects ARPA-H to fi­nal­ize plan for han­dling du­pli­cate re­search

Last year
R&D
FDA+

ACIP rec­om­mends ex­pand­ed use for Val­neva's chikun­gun­ya vac­cine and Covid boost­ers

Last year

In­smed en­cour­ages peo­ple to 'S­peak Up' in new mar­ket­ing ef­fort

Last year
Marketing

UK re­lies on EMA's re­view of Xge­va re­for­mu­la­tion in first-ever rec­i­p­ro­cal ap­proval

Last year

Judge rules against As­traZeneca in suit over IRA price ne­go­ti­a­tions

Last year
Law

House com­mit­tee de­bates IRA changes that would im­pact or­phan drugs and oth­er ar­eas

Last year
FDA+

Phar­ma lags be­hind health­care in AI adop­tion, but many ex­pect wider use in next few years, study finds

Last year
Marketing

Bel­har­ra CEO talks the ins and outs of build­ing a biotech in a new pod­cast

Last year
Marketing

San­doz pays out $265M to set­tle part of an­titrust law­suit

Last year
Law

Biden ad­min­is­tra­tion in­vests $48M in AI/ML plat­form to iden­ti­fy rare dis­ease drugs

Last year
AI
FDA+

Sarep­ta touts Duchenne gene ther­a­py up­take, but warns of de­mand flat­ten­ing be­fore po­ten­tial ex­pand­ed la­bel from FDA

Last year
Cell/Gene Tx

Io­vance’s Am­tagvi sees ‘healthy de­mand’ af­ter US ap­proval

Last year
Cell/Gene Tx
Manufacturing

No­vo Nordisk plans for life af­ter We­govy, set­ting up roots in Boston to try and find its fu­ture

Last year
R&D

Ar­genx rolls out new cam­paign for rare au­toim­mune con­di­tion as it awaits FDA rul­ing

Last year
Marketing

Mod­er­na spells out rare dis­ease am­bi­tions: 'We have a bunch of INDs planned'

Last year
FDA+

Califf lays out drug short­age land­scape, talks post-mar­ket da­ta col­lec­tion for ac­cel­er­at­ed ap­provals

Last year
FDA+
Manufacturing

Jor­dan­ian OTC drug man­u­fac­tur­er re­ceives FDA warn­ing let­ter over mul­ti­ple ‘un­ac­cept­able haz­ards’

Last year
Manufacturing

Bris­tol My­ers eyes In­dia as home of its largest site out­side US by 2025, maps $400M Ire­land ex­pan­sion

Last year
R&D
Manufacturing

Ther­at­e­ch­nolo­gies hit with FDA refuse to file let­ter for in­tra­mus­cu­lar ver­sion of HIV drug

Last year
FDA+

Min­er­va's shares sink on re­jec­tion of schiz­o­phre­nia drug

Last year
FDA+

DOJ sub­poe­nas Bio­Marin over spon­sored test­ing pro­gram for rare dis­ease drugs

Last year
FDA+

Phar­ma con­sid­ers al­ter­na­tives to large sales forces

Last year
Marketing
First page Previous page 70717273747576 Next page Last page
A service from the Financial Times